AU2022262421A1 - Anti-tslp antibody compositions and uses thereof - Google Patents

Anti-tslp antibody compositions and uses thereof Download PDF

Info

Publication number
AU2022262421A1
AU2022262421A1 AU2022262421A AU2022262421A AU2022262421A1 AU 2022262421 A1 AU2022262421 A1 AU 2022262421A1 AU 2022262421 A AU2022262421 A AU 2022262421A AU 2022262421 A AU2022262421 A AU 2022262421A AU 2022262421 A1 AU2022262421 A1 AU 2022262421A1
Authority
AU
Australia
Prior art keywords
antibody compositions
tslp antibody
tslp
compositions
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022262421A
Other languages
English (en)
Inventor
Kristin ABRAMS
Kelly Fitzpatrick
Marisa JOUBERT
Alla Polozova
Dong Xiang
Hao Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2022262421A1 publication Critical patent/AU2022262421A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022262421A 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof Pending AU2022262421A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
US63/178,938 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU2022262421A1 true AU2022262421A1 (en) 2023-10-19

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022262421A Pending AU2022262421A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Country Status (19)

Country Link
US (1) US20240190951A1 (https=)
EP (1) EP4326766A1 (https=)
JP (1) JP2024517418A (https=)
KR (1) KR20240000537A (https=)
CN (1) CN117203233A (https=)
AR (1) AR125408A1 (https=)
AU (1) AU2022262421A1 (https=)
BR (1) BR112023021867A2 (https=)
CA (1) CA3216655A1 (https=)
CL (1) CL2023003155A1 (https=)
CO (1) CO2023014181A2 (https=)
CR (1) CR20230531A (https=)
IL (1) IL307540A (https=)
JO (1) JOP20230265A1 (https=)
MX (1) MX2023012363A (https=)
PE (1) PE20240068A1 (https=)
TW (1) TW202308690A (https=)
UY (1) UY39736A (https=)
WO (1) WO2022226339A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
IL324470A (en) 2023-05-18 2026-01-01 Medimmune Llc Treatment of corticosteroid-dependent asthma using anti-TSLP antibody
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
CN102281901A (zh) * 2008-11-20 2011-12-14 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2015116315A1 (en) 2014-01-29 2015-08-06 Amgen Inc. Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
FI3218005T3 (fi) * 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
ES2978396T3 (es) * 2017-08-01 2024-09-11 Amgen Inc Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
JP7562563B2 (ja) 2019-04-30 2024-10-07 アムジエン・インコーポレーテツド バイオ医薬品生産における細胞株選択のためのデータ駆動予測モデリング
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins

Also Published As

Publication number Publication date
TW202308690A (zh) 2023-03-01
JP2024517418A (ja) 2024-04-22
JOP20230265A1 (ar) 2023-10-22
KR20240000537A (ko) 2024-01-02
PE20240068A1 (es) 2024-01-11
CR20230531A (es) 2024-01-08
AR125408A1 (es) 2023-07-12
MX2023012363A (es) 2023-11-01
CO2023014181A2 (es) 2023-10-30
EP4326766A1 (en) 2024-02-28
CL2023003155A1 (es) 2024-04-19
CN117203233A (zh) 2023-12-08
BR112023021867A2 (pt) 2023-12-19
WO2022226339A9 (en) 2023-08-24
CA3216655A1 (en) 2022-10-27
UY39736A (es) 2022-10-31
WO2022226339A1 (en) 2022-10-27
US20240190951A1 (en) 2024-06-13
IL307540A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
AU2022262421A1 (en) Anti-tslp antibody compositions and uses thereof
AU2022344251A1 (en) Serpina-modulating compositions and methods
AU2022342169A1 (en) Hbb-modulating compositions and methods
AU2022342168A1 (en) Pah-modulating compositions and methods
CA3260121A1 (en) ANTI-GAL3 ANTIBODIES AND COMPOSITIONS
HK40107489A (en) Anti-tslp antibody compositions and uses thereof
EP4288062A4 (en) FOSPROPOFOL METHODS AND COMPOSITIONS
AU2024359227A1 (en) Anti-tslp antibodies and uses thereof
CA3307609A1 (en) Anti-tslp antibodies and uses thereof
HK40117236A (en) Compositions and methods comprising anti-nrp2a antibodies
CA3300108A1 (en) Anti-gprc5d antibodies and compositions
HK40105651A (en) Anti-siglec compositions and uses thereof
HK40115055A (en) Novel anellovector compositions and methods
AU2021902682A0 (en) Compositions and uses thereof
AU2021902267A0 (en) Compositions and uses thereof
HK40093046A (en) Compositions and uses thereof
AU2021901822A0 (en) Compositions and uses thereof
CA3295097A1 (en) Compositions and uses thereof
CA3295099A1 (en) Compositions and uses thereof
CA3292483A1 (en) Maribavir compositions and uses thereof
AU2023903761A0 (en) Compositions and uses thereof
HK40128580A (en) Compositions and uses thereof
HK40127555A (en) Compositions and uses thereof
AU2023902369A0 (en) Compositions and uses thereof
AU2020904491A0 (en) Compositions and uses thereof